<DOC>
	<DOCNO>NCT00720668</DOCNO>
	<brief_summary>This study aim find risk exacerbation chronic hepatitis B percutaneous radiofrequency ablation ( RFA ) hepatectomy HCC , 's effect treatment outcome .</brief_summary>
	<brief_title>The Risk Exacerbation Chronic Hepatitis B After Percutaneous Radiofrequency Ablation Hepatocellular Carcinoma</brief_title>
	<detailed_description>It report HBV replication react chemotherapy immunotherapy , lead exacerbation chronic hepatitis B ( ECHB ) . It still unknown percutaneous radiofrequency ablation liver resection hepatocellular carcinoma ( HCC ) react replication HBV . This study aim find risk exacerbation chronic hepatitis B percutaneous radiofrequency ablation ( RFA ) hepatectomy HCC , 's effect treatment outcome .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Age 18 75 year HBV carrier HCC After percutaneous radiofrequency ablation ; No history encephalopathy , ascites refractory diuretic variceal bleed No HCV HIV coinfection No previous treatment HCC No previous treatment HBV except Lamivudine Patient compliance poor Active clinically serious infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 ) Known history human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumor include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry Distantly extrahepatic metastasis History organ allograft Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Excluded therapy medication , previous concomitant Prior use systemic anticancer treatment HCC , eg . chemotherapy , immunotherapy hormonal therapy ( except hormonal therapy supportive care permit ) . Antiviral treatment allow , however interferon therapy must stop least 4 week prior randomization Prior use systemic investigational agent HCC Autologous bone marrow transplant stem cell rescue within four month start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>radiofrequency ablation</keyword>
	<keyword>reactivation</keyword>
</DOC>